ReviewPharmaceutical research2017
The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.
Review in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.Journal of aerosol medicine and pulmonary drug delivery · 2019Trial
- Spray-Dried Formulations of Relaxin-H2 for Inhalation.Pharmaceutical research · 2026Article
- Advancing pulmonary therapy: the role of dry powder inhalation technology in lung disease management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Development of an AI-Empowered Novel Digital Monitoring System for Inhalation Flow Profiles.Sensors (Basel, Switzerland) · 2025Article
- An In Vitro Dissolution Method for Inhaled Drugs Depositing in the Tracheobronchial Lung Region.Pharmaceutical research · 2025Article
- Scale-Up and Postapproval Changes in Orally Inhaled Drug Products: Scientific and Regulatory Considerations.Journal of aerosol medicine and pulmonary drug delivery · 2025Review
- Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer.Pharmaceutics · 2024Review
- Flowrate Sensing and Measurement in Portable Smart Inhalers.Sensors (Basel, Switzerland) · 2024Review
- Pulmonary inhalation for disease treatment: Basic research and clinical translations.Materials today. Bio · 2024Review
- Usability of inhaler devices: a parameter currently misused.Multidisciplinary respiratory medicine · 2024Article
- The effect of lung emptying before the inhalation of aerosol drugs on drug deposition in the respiratory system.International journal of pharmaceutics: X · 2023Article
- Development of Large Hollow Particles for Pulmonary Delivery of Cyclosporine A.Pharmaceutics · 2023Article
- Evaluation of Peak Inspiratory Flow Rate in Hospitalized Palliative Care Patients with COPD.Pharmacy (Basel, Switzerland) · 2023Article
- Inhalable Nanoparticle-based Dry Powder Formulations for Respiratory Diseases: Challenges and Strategies for Translational Research.AAPS PharmSciTech · 2023Review
- Pulmonary drug delivery for acute respiratory distress syndrome.Pulmonary pharmacology & therapeutics · 2023Review
- Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and Biotherapeutics.Pharmaceutical research · 2022Review
- Spatial aerosol deposition correlated to anatomic feature development in 6-year-old upper airway computational models.Computers in biology and medicine · 2022Article
- Lung Function Can Predict the Expected Inspiratory Airflow Rate through Dry Powder Inhalers in Asthmatic Adolescents.Children (Basel, Switzerland) · 2022Article
- Targeting of Inhaled Therapeutics to the Small Airways: Nanoleucine Carrier Formulations.Pharmaceutics · 2021Article
- Optimizing Spray-Dried Porous Particles for High Dose Delivery with a Portable Dry Powder Inhaler.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current marketed dry powder inhalers utilize the energy from patient inspiration to fluidize and disperse bulk powder agglomerates into respirable particles. Variations in patient inspiratory flow profiles can lead to marked differences in total lung dose (TLD), and ultimately patient outcomes for an inhaled therapeutic. The present review aims to quantitate the flow rate dependence in TLD observed for a number of drug/device combinations using a new metric termed the Q index. With this data in hand, the review explores key attributes in the design of the formulation and device that impact flow rate dependence. The review also proposes alternative in vitro methods to assess flow rate dependence that more closely align with in vivo observations. Finally, the impact of variations in flow rate on lung function for inhaled bronchodilators is summarized.
Indexed as
Identifiers
27738953What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.